Therapy Areas: Devices
Teva awarded FDA approval for AJOVY (fremanezumab-vfrm) Injection Autoinjector for migraine treatment
29 January 2020 -

Teva Pharmaceuticals USA Inc reported on Tuesday the receipt of approval from the Food and Drug Administration (FDA) for an autoinjector device for AJOVY (fremanezumab-vfrm) injection for treating migraine.

AJOVY is the only FDA-approved anti-CGRP that offers the flexibility of quarterly (675 mg) or monthly (225 mg) dosing options and the healthcare providers will be able to decide if an autoinjector is the right administration option for their needs.

In conjunction, the company's AJOVY autoinjector is expected to be available to patients in the coming months.

Teva Pharmaceuticals USA Inc is an affiliate of Teva Pharmaceutical Industries Ltd. (NYSE:TEVA)( TASE:TEVA), which has been developing and producing medicines to improve people's lives for more than a century.

Login
Username:

Password: